Edgewise Therapeutics (Edgewise Therapeutics) Float Percentage Of Total Shares Outstanding : 67.96% (As of Jun. 07, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Edgewise Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Edgewise Therapeutics's float shares is 63.47 Mil. Edgewise Therapeutics's total shares outstanding is 93.40 Mil. Edgewise Therapeutics's float percentage of total shares outstanding is 67.96%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Edgewise Therapeutics's Insider Ownership is 0.15%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Edgewise Therapeutics's Institutional Ownership is 25.26%.

Edgewise Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Edgewise Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	63.47	/	93.40
	=	67.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edgewise Therapeutics (Edgewise Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edgewise Therapeutics Inc (NAS:EWTX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3415 Colorado Avenue, Boulder, CO, USA, 80303

Website

https://www.edgewisetx.com

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Executives

John R Moore	officer: General Counsel	3200 WALNUT ST, BOULDER CO 80301
Alan J Russell	director, officer: Chief Scientific Officer	3415 COLORADO AVE, BOULDER CO 80303
Jonathan C Fox	director	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Behrad Derakhshan	officer: Chief Business Officer	3415 COLORADO AVE., BOULDER CO 80303
Kevin Koch	director, officer: President and CEO	3200 WALNUT ST, BOULDER CO 80301
Joanne M. Donovan	officer: CMO	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139
Marc Semigran	officer: Chief Development Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Orbimed Capital Gp Vi Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan D Root	director	2735 SAND HILL ROAD, MENLO PARK CA 94025
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017